Idarubicin
Title: Idarubicin
CAS Registry Number: 58957-92-9
CAS Name: (7S,9S)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione
Additional Names: (1S,3S)-3-acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; 4-demethoxydaunomycin; 4-demethoxydaunorubicin; DMDR
Manufacturers' Codes: IMI-30; NSC-256439
Molecular Formula: C26H27NO9
Molecular Weight: 497.49
Percent Composition: C 62.77%, H 5.47%, N 2.82%, O 28.94%
Literature References: Orally active anthracycline; analog of daunorubicin, q.v. Prepn: B. Patelli et al. DE 2525633; eidem, US 4046878 (1976, 1977 both to Soc. Farmac. Ital.); and antitumor activity: F. Arcamone et al., Cancer Treat. Rep. 60, 829 (1976). Total synthesis for larger scale preparation: M. J. Broadhurst et al., Chem. Commun. 1982, 158. Synthesis of optically pure isomers: Y. Kimura et al., Bull. Chem. Soc. Jpn. 59, 423 (1986). Metabolism and biodistribution in rats: G. Zini et al., Cancer Chemother. Pharmacol. 16, 107 (1986). HPLC determn in plasma: S. S. N. De Graaf et al., J. Chromatogr. 491, 501 (1989). Clinical pharmacokinetics: H. C. Gillies et al., Br. J. Clin. Pharmacol. 23, 303 (1987). Clinical evaluation of cardiac toxicity: F. Villani et al., Eur. J. Cancer Clin. Oncol. 25, 13 (1989). Reviews of pharmacology and antitumor efficacy: A. M. Casazza, Cancer Treat. Rep. 63, 835-844 (1979); F. Ganzina et al., Invest. New Drugs 4, 85-105 (1986). Symposium on clinical experience in acute leukemias: Semin. Oncol. 17, Suppl. 2, 1-36 (1989).
 
Derivative Type: Hydrochloride
CAS Registry Number: 57852-57-0
Trademarks: Idamycin (Pharmacia & Upjohn); Zavedos (Pharmacia & Upjohn)
Molecular Formula: C26H27NO9.HCl
Molecular Weight: 533.95
Percent Composition: C 58.48%, H 5.29%, N 2.62%, O 26.97%, Cl 6.64%
Properties: Orange crystalline powder, mp 183-185° (Arcamone); also reported as mp 172-174° (Broadhurst). [a]D20 +205° (c = 0.1 in methanol) (Arcamone); also reported as [a]D20 +188° (c = 0.10 in methanol) (Kimura).
Melting point: mp 183-185° (Arcamone); mp 172-174° (Broadhurst)
Optical Rotation: [a]D20 +205° (c = 0.1 in methanol) (Arcamone); [a]D20 +188° (c = 0.10 in methanol) (Kimura)
 
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Antibiotics and Analogs; Anthracyclines; Topoisomerase II Inhibitor.

Others monographs:
DibromsalicilAmmonium HypophosphiteMorazoneAmmonium Ferrous Sulfate
Cuprous ThiocyanateEnterobactinVinflunineMonarda
BethanidineOil of ThymeApholateCetiedil
Silver2,5-TetrahydrofurandimethanolProcerinDiphacinone
©2016 DrugLead US FDA&EMEA